FDA grants approval of lonafarib for Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies

Approval of lonafarib, an oral farnesyltransferase inhibitor, in patients > 1year of age, is based on two single-arm trials (n=62) which reported reduction in mortality by 60% (p=0.0064) and increased average survival time by 2.5 years vs matched untreated patients.

Source:

Biospace Inc.